GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Share News (COG)

Share Price Information for Cambridge Cog (COG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 42.00
Bid: 41.00
Ask: 43.00
Change: 0.00 (0.00%)
Spread: 2.00 (4.878%)
Open: 42.00
High: 42.00
Low: 42.00
Prev. Close: 42.00
COG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Evgen disappointed as SFX-01 flops study hurdle

Fri, 09th Jul 2021 10:52

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

----------

AIM - WINNERS

----------

Cambridge Cognition Holdings PLC, up 8.1% at 177.8 pence, 12-month range 35.1p-188p. Wins GBP1 million contract as cognitive assessment partner for a late phase cancer trial. Revenue from the contract is expected to be recognised over the next six years. "This is the second contract for a top ten pharmaceutical company with a strong pipeline of oncology products," the digital neuroscience company notes.

----------

Open Orphan, up 7.4% at 26.85p, 12-month range 11.5p-48p. Subsidiary hVIVO signs "significant" contract with AIM ImmunoTech Inc to test its antiviral candidate, Ampligen, using both the human Rhinovirus HRV and Influenza human challenge study models as part of a single study. This antiviral study will be conducted by hVIVO. The pharmaceutical services firm expects majority of revenue from the contract to be recognised in the current financial year. "As previously confirmed to the market, our London facilities are comprehensively prebooked throughout this year and into next year. As such, I am also delighted to confirm that we were solidly Ebitda profitable in H1 2021 and we remain on target for a profitable and successful 2021," says Open Orphan Executive Chair Cathal Friel.

----------

AIM - LOSERS

----------

Evgen Pharma PLC, down 30% at 5.19p, 12-month range 4.22p-15.76p. The clinical stage drug development company is "surprised and disappointed" after being informed that independent data management committee concludes analyses of SFX-01 in Star Covid-19 study did not meet the interim futility hurdle required to continue the study, and that active treatment would not be likely to show an overall statistically significant improvement. Recruitment into trial to be halted. "We are surprised and disappointed by these findings given the strong preclinical hypothesis surrounding sulforaphane as an Nrf2 activator with potential direct antiviral properties," says Chief Executive Huw Jones.

----------

Empyrean Energy PLC, down 24% at 6.43p, 12-month range 3.05p-9p. The oil and gas development company raises GBP5.0 million via placing of 83.7 million shares at price of 6.0p each. "Funds raised under this placing will primarily be used to secure a suitable drilling rig and order long lead items and for the Company's general working capital requirements as it prepares to drill the Jade prospect at its 100% owned Block 29/11 license in China, scheduled for late 2021," it says.

----------

Ilika PLC, down 24% at 153p, 12-month range 56.4p-285p. The advanced solid-state battery company plans placing of up to 12.8 million shares at price of 140p each to raise GBP18.0 million. Also intends to raise up to further GBP3.7 million through open offer, and will also make retail offer for up to GBP3.0 million via PrimaryBid. In total, eyes raising total gross proceeds of GBP24.7 million. "The net proceeds of the capital raising are expected to support the development of Ilika's solid-state electric vehicle pouch cells through its Goliath programme until the programme reaches and exceeds Lithium Ion Battery equivalence," it says.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
19 Dec 2018 08:52

Cambridge Cognition shares tumble as revenues fall short of expectations

(Sharecast News) - Neuroscience technology developer Cambridge Cognition has seen revenues fall short of expectations and losses widen as a result of a switch in accounting practices.

Read more
20 Sep 2018 12:35

Cambridge Cognition Holdings Loss Widens As Revenue Drops

LONDON (Alliance News) - Cambridge Cognition Holdings PLC said Thursday that its loss for the first half of the financial year widened as it recorded a drop in revenue as a result of the new IFRS

Read more
19 Sep 2018 12:45

Cambridge Cognition To Provide NeuroVocalix For Virtual Clinical Tests

LONDON (Alliance News) - Cambridge Cognition Holdings PLC on Wednesday said it signed its first commercial contract with an undisclosed pharmaceutical firm for its recently launched NeuroVocalix a

Read more
19 Sep 2018 10:14

Cambridge Cognition announces first NeuroVocalix commercial partnership

(Sharecast News) - Neuroscience technology company Cambridge Cognition Holdings announced its first commercial partnership for its recently launched 'NeuroVocalix' voice biomarker technology on Wednesday.

Read more
13 Sep 2018 11:14

Cambridge Cognition's NeuroVocalix Set For Clinical Trial Use

LONDON (Alliance News) - Neuroscience technology firm Cambridge Cognition Holdings PLC on Thursday said its NeuroVocalix platform is ready for clinical trials.NeuroVocalix, the company to a

Read more
1 Aug 2018 11:51

Cambridge Cognition Inks US Production Distribution For CANTAB

LONDON (Alliance News) - Cambridge Cognition Holdings PLC said Wednesday that it signed a commercial collaboration with health provider Healthy Amplified to launch its software product to better a

Read more
17 May 2018 16:01

UK Shareholder Meetings Calendar - Next 7 Days

Friday 18 MayPaddy Power BetfairIndependent News & (T)PetrofacJohn Group (re by

Read more
22 Mar 2018 13:03

Cambridge Cognition Shares Fall As It Swings To Annual Loss

LONDON (Alliance News) - Shares fell in Cambridge Cognition Holdings PLC on Thursday as it swung to a loss in 2017 from a maiden profit due to higher costs and lower in the at

Read more
14 Mar 2018 12:47

Oil majors give in to investors with share buyback spree

By Nivedita Bhattacharjee March 14 (Reuters) - After almost three barren years for investors who have poured millions into the U.S. oil sector, producers are finally to

Read more
25 Jan 2017 08:27

Cambridge Cognition gains US regulatory approval for memory test

(ShareCast News) - Neuroscience digital health company Cambridge Cognition has gained regulatory clearance for its memory test to be used as a medical device in the US. Cantab Mobile, which detects clinically-relevant memory impairment in older adults at the point of care, received 510k clearance fo

Read more
13 Oct 2016 10:55

Cambridge Cognition confirms series of new contracts

(ShareCast News) - Neuroscience company Cambridge Cognition Holdings announced a series of new contracts worth more than £0.25m on Thursday, to assess - through CANTAB Connect - the abuse potential of investigational drugs in a new market application for the company. The AIM-traded firm claimed that

Read more
22 Sep 2016 10:23

Cambridge Cognition's sales up after investments in marketing

(ShareCast News) - Cambridge Cognition' half-year revenues grew and losses were more than halved as the neuroscience software and hardware company's invested in marketing and development. For the six months ended 30 June, revenue increased by 11.3% to £3.26, compared to the same period last year. T

Read more
22 Sep 2016 08:51

Cambridge Cognition Loss Narrows On Strong Revenue Growth

Read more
20 Sep 2016 08:07

Cambridge Cognition Inks First Contract For CANTAB Recruit Product

Read more
16 Aug 2016 13:49

Cambridge Cognition announces promising results from technology study

(ShareCast News) - Neuroscience company Cambridge Cognition Holdings announced results on Tuesday from a new technology feasibility study. The AIM-traded firm, which develops and markets near-patient technologies for the assessment of brain health to improve the drug development process, said the re

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.